First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer

BACKGROUND: BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of BPI-9016M in Chinese patients with advanced non-small...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingsheng, Zheng, Xin, Yang, Sheng, Wang, Lin, Hao, Xuezhi, Cui, Xinge, Ding, Lieming, Mao, Li, Hu, Pei, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966871/
https://www.ncbi.nlm.nih.gov/pubmed/31948451
http://dx.doi.org/10.1186/s13045-019-0834-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966871/
https://www.ncbi.nlm.nih.gov/pubmed/31948451
http://dx.doi.org/10.1186/s13045-019-0834-2

Ejemplares similares